Quality Systems and the Cost of Non-Compliance

The problem exists where Pharmaceutical and Biotech leaders do not fully understand the financial and emotional impact of non-compliance with cGMP's. The Cost of Non Compliance reviews remediation efforts of three Consent Decrees from pharmaceutical and biotech companies as experienced by the author. Participants will review actual financial data to see the impact Consent Decrees have on investor confidence, stock prices and budgets. Understand the financial impact of Consent Decrees, understand the emotional impact on employees during a Consent Decree, apply Leadership tactics and strategies to manage the emotional impact.